SSY Group Limited
SSY Group Limited
Your view on LJUIF
Overview
What the company does, where it operates, and who runs it.
About SSY Group Limited
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Jiguang Qu
- Headquarters
- Central Plaza, Wan Chai, HK
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Jiguang Qu
- Headquarters
- Central Plaza, Wan Chai, HK
SSY Group Limited, an investment holding company, researches, develops, manufactures, and sells various pharmaceutical products to hospitals and distributors in the People's Republic of China and internationally.
The company offers intravenous infusion solutions, including non-PVC soft bags, upright soft bags, PP plastic bottles, and glass bottle infusion solutions, as well as ampoule injections.
It also provides small volume injections, oral preparations, Chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials.
In addition, the company is involved in the research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; and food, beverages, and catering business. It sells its products under Shimen brand name.
The company was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. and changed its name to SSY Group Limited in May 2015. The company was incorporated in 2004 and is headquartered in Wanchai, Hong Kong. SSY Group Limited is a subsidiary of China Pharmaceutical Co., Ltd.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for SSY Group Limited, and the rating behind it. LJUIF last traded at $0.40, 15.0× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for SSY Group Limited. Starting points for SSY Group Limited: P/E 15.0, EPS $0.18, beta 0.54 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for SSY Group Limited. SSY Group Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for SSY Group Limited. Trailing twelve-month EPS for SSY Group Limited stands at $0.18. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for SSY Group Limited. SSY Group Limited has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
SSY Group Limited valued side by side against its closest peers. SSY Group Limited is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold SSY Group Limited, and how their positions are changing. At a $1.19B market value, institutional positions materially move SSY Group Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by SSY Group Limited executives and directors. Shares of SSY Group Limited have traded between $0.40 and $0.70 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming SSY Group Limited. SSY Group Limited is a $1.19B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming SSY Group Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for SSY Group Limited. Coverage tracks SSY Group Limited within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.